PRESS RELEASE Loudéac, 31 March 2026WINFARM reports a strong improvement in its 2025 full-year resultsEBITDA of €5.3 million (3.6% of revenue), i.e. multiplied by a factor of 4 almost Cash flow generation of €1.4 million Reduction in net financial debt of €7 millionOutlook for 2026Continued cash generation and debt reduction driven by a further improvement in EBITDAWINFARM (ISIN: FR0014000P11 – ticker: ALWF), the leading French player in distance-selling of products and solutions for the agricultural industry, today published its consolidated results for the 2025 financial year, as approved by the Board of Directors at its meeting of 31 March 2026 and audited by the statutory auditors. The certification reports are currently being drawn up. The consolidated financial statements for the 2025 financial year are available...

SOCIETE GENERALE SCF: AVAILABILITY OF THE ANNUAL FINANCIAL REPORT FOR 2025 Regulated Information Paris, 31 March 2026 Societe Generale SCF (“Société de Crédit Foncier”, Public Sector Loans) hereby informs the public that the Annual Financial Report for the period ended 31 December 2025, has been filed with the French financial markets authority (The Autorité des Marchés Financiers – AMF) on 31 March 2026. This document, available in French only, is made available to the public, free of charge, in accordance with the conditions provided for by the regulations in force and may be consulted in the “Societe Generale Public Sector Loans SCF / Regulated information” section of the Societe Generale group’s website and on the AMF’s website. Press contacts:Jean-Baptiste Froville_+33 1 58 98 68 00_ jean-baptiste.froville@socgen.com Fanny Rouby_+33...

Proactis SA Announces Financial Information for the year ended 31 January 2026 Paris – March 31, 2026 – Proactis SA (Euronext: PROAC), a leading provider of comprehensive spend management and business process collaboration solutions, today announces financial information for the year ended 31 January 2026, in accordance with the “European Transparency Obligations Directive” financial disclosure requirements. Financial datain € million     Year ended 31 Jan 2026   Year ended 31 Jan 2025     % Change2026/2025(*)                 Consolidated Operational Revenue     4.7   5.5     (15) %SaaS (**)     4.4   5.0     (13) %Services     0.3   0.4     (37) %                 Management fees     4.6   3.8     21 %                 Consolidated Revenue     9.3   9.3     0 %(unaudited Figures)                (*) Percentages...

Overview of 2025 annual resultsConsolidated net profit was EUR 74.9 million (EUR 82.1 million in 2024) Allocation of profit proposal to the Annual General Meeting of 12 May 2026: gross dividend of EUR 1.40 per share (2025: EUR 1.40 per share) Large flows to Germany and the Netherlands continue Additional transmission capacity from the west under construction The number of loaded LNG trucks in Zeebrugge is growing 73% more bio-LNG at the Zeebrugge terminal Start of construction on initial hydrogen and CO2 infrastructure Fluxys c-grid appointed as CO2 network operator in Wallonia and Flanders Boosting Belgium as a CO2 hub in North-West Europe Strong results across multiple ESG objectives 102 new colleagues hired  Key financial dataIncome statement (in thousands of EUR) 31/12/2025 31/12/2024Operating revenue 650,453 608,789EBITDA* 320,111 302,283EBIT* 133,916 133,931Net...

31/03/2026 EBITDA margin at 7.6%, in line with the targetNet income impacted by significant non-cash depreciations,strongly positive Free Cash Flow (+€36.6m) and sharp reduction in net debt Moderate revenue growth and maintained EBITDA margin expected in 2026Full confirmation of 2027 financial targets€m 2025   2024restated for North America   2024 non-restatedRevenue 445.5 494.4 635.5Recurring EBITDA 34.1 39.0 25.4as % of revenue 7.6% 7.9% 4.0%Recurring operating income 21.1 26.3 5.2as % of revenue 4.7% 5.3% 0.8%Opertaing income 17.0 19.7 (20.8)Financial result (3.3) (7.3) (12.5)Income tax (4.8) (4.5) (0.3)Net income from continuing operations 8.9 7.8 (33.5)Net income from discontinued operations* (56.0) (57.0) (15.7)Consolidated net income (47.1) (49.2) (49.2)Net income, Group share (39.7) (33.8) (33.8)*Discontinued...

Earnings Call Webcast to Discuss 2025 Fourth Quarter and Full Year Financial Results Scheduled to Post to Corporate Website by Thursday, April 02, 2026 NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) — Reading International, Inc. (NASDAQ: RDI) (“Reading” or our “Company”), an internationally diversified cinema and real estate company with operations and assets in the United States, Australia, and New Zealand, today reported its results for the fourth quarter and year ended December 31, 2025. Key Financial Results – Fourth Quarter 2025 compared to Fourth Quarter 2024Total Revenues were $50.3 million compared to $58.6 million in Q4 2024. Operating Loss was $1.0 million compared to Operating Income of $1.5 million in Q4 2024. Net Loss was $2.6 million compared to a Net Loss of $2.2 million in Q4 2024. Basic Loss per Share was $0.11 compared...

PLAINVIEW, N.Y., March 31, 2026 (GLOBE NEWSWIRE) — Vaso Corporation (“Vaso”) (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and IT services, professional sales services, and proprietary medical products, today announced its operating results for the three months and year ended December 31, 2025. “The Company’s annual revenue reached a record $89.1 million for the fiscal year 2025, an increase of $2.3 million, or 3%, when compared to the prior year’s revenue, despite the sale of its healthcare IT business unit in November 2025,” commented Dr. Jun Ma, President and Chief Executive Officer of Vaso Corporation. “Gross profit for 2025 was $54.7 million, up by $2.6 million, or 5% year-over-year, and net income for 2025 increased to $1.6 million from $951 thousand in 2024, mainly due to the increase...

The group continues expanding into North America and across key global markets, driven by demand for its AI-powered Exposure Management Platform that unifies Cyber Threat Intelligence, External Attack Surface Management, and Third-Party Risk Tel Aviv, Israel, March 31, 2026 (GLOBE NEWSWIRE) — NEW YORK, NY and TEL AVIV, ISRAEL – March 31, 2026 – KELA Group, a global leader in Cyber Threat Intelligence and Exposure Management, today announced record growth for its previous fiscal year. As enterprises favor unified exposure management and proactive cyber defense strategies, KELA Group has seen accelerating market adoption, achieving a 101% year-over-year (YoY) growth in bookings and the highest number of 5-star reviews in its Gartner Peer Insights category. These achievements are further reflected in the acceleration of customer acquisition...

CEO AND CFO PROVIDE GROUNDBREAKING AI ANIMATED EARNINGS UPDATE IN INTERVIEW WITH A.A. MILNE’S WINNIE THE POOH, AND TENTPOLE CHARACTERSOVERALL REVENUE INCREASED YEAR-OVER-YEAR 21% IN 2025 TO $39.4 MILLION PRODUCTION SERVICES REVENUE INCREASED 50% YEAR-OVER-YEAR TO $26.8 MILLION KARTOON CHANNEL WATCH TIME SURGES 85% YEAR-OVER-YEAR, AMIDST RECORD SUBSCRIBERS AND BREAKOUT ENGAGEMENT ACROSS SVOD AND FAST PLATFORMS, AS GLOBAL DIGITAL DISTRIBUTION ECOSYSTEM SCALES KARTOON CHANNEL CONTINUES TO LEAD ALL COMPETITORS IN APPLE APP STORE VIEWER RATINGSOPERATING LOSS IMPROVES 24%; COMPANY TRANSITIONS TO HIGH-MARGIN FRANCHISE MONETIZATION IP-DRIVEN BUSINESS MODEL-NOT DEPENDENT ON ENERGY INPUT COSTS-POSITIONS COMPANY FOR RESILIENT, SCALABLE GROWTH IN A RISING COST ENVIRONMENT BEVERLY HILLS, Calif., March 31, 2026 (GLOBE NEWSWIRE) — Kartoon...

Encouraging Phase 2 HIT data and recent FDA feedback support continued advancement of CAD-1005 as Cadrenal’s near-term development priority; broader 12-LOX platform remains a longer-term opportunity PONTE VEDRA, Fla., March 31, 2026 (GLOBE NEWSWIRE) — Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions, today reported its financial results for the fourth quarter and full year ended December 31, 2025, and provided a corporate update highlighting recent progress across its CAD-1005 program for HIT and broader 12-LOX inhibitor platform. The update reflects continued progress for CAD-1005, Cadrenal’s first-in-class 12-LOX inhibitor for suspected heparin-induced thrombocytopenia (HIT), including completion of its End-of-Phase...